-
Mashup Score: 15
Even though crossing aortic valves isn’t a lost art, crossing may be more difficult for novice operators because of a lack of everyday practice in the cath lab.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Cardiology News and JournTweet
-
Mashup Score: 7Aortic Valve Area and Time to Cross the Aortic Valve in Severe Aortic Stenosis During Transfemoral TAVR - 16 day(s) ago
In this study of 136 patients at a single center, the authors determined smaller aortic valve areas (AVAs) in patients with aortic stenosis are significantly associated with increased time to cross the aortic valve.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Cardiology News and JournTweet-
Aortic Valve Area (AVA) and Time to Cross During Transfemoral TAVR Casazza, Fogel, Shani A smaller AVA in patients with aortic stenosis is significantly associated with increased time to cross the aortic valve. https://t.co/LXVoaYtJMA @InvasiveCardiol #cardiotwitter https://t.co/IY7yFObgNz
-
-
Mashup Score: 3
This study demonstrates that ATTRv should be investigated systematically in patients diagnosed with IVIg-NR CIDP. HCP-directed information campaigns are useful for modifying diagnostic practices.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
A very high-yield vignette CIDP that is resistant to typical treatments such as IVIg --> test for TTR variant In general, any polyneuropathy should lead to TTR gene variant testing Sponsored testing is free https://t.co/uLZjqO1LaJ #CardioTwitter https://t.co/hPlrJDhBuU
-
-
Mashup Score: 0
Providers must develop and integrate an ambulatory strategy into their overarching cardiovascular strategic plan, whether through joint ventures, acquisition, or other alignment structures with existing ASCs, or through investment into their own facility(ies), because this growing shift is imminent in all markets for cardiology.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Cardiology News and JournTweet-
🚨 "A Shift in Cardiovascular Care: ASCs, PAD, and PVI" 🚨 Michael Church, Director, and Amy Newell, Senior Vice President at Corazon, Inc. Is this the next big transformation in vascular health? 🔗 Read more: https://t.co/1FXChIuDdv #cardiotwitter https://t.co/trE3R1EFg0
-
-
Mashup Score: 0
Providers must develop and integrate an ambulatory strategy into their overarching cardiovascular strategic plan, whether through joint ventures, acquisition, or other alignment structures with existing ASCs, or through investment into their own facility(ies), because this growing shift is imminent in all markets for cardiology.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Cardiology News and JournTweet-
🚨 "A Shift in Cardiovascular Care: ASCs, PAD, and PVI" 🚨 Michael Church, Director, and Amy Newell, Senior Vice President at Corazon, Inc. Is this the next big transformation in vascular health? 🔗 Read more: https://t.co/e7TXukIJK1 @InvasiveCardiol #cardiotwitter https://t.co/2Djv6xhg3V
-
-
Mashup Score: 2
Providers must develop and integrate an ambulatory strategy into their overarching cardiovascular strategic plan, whether through joint ventures, acquisition, or other alignment structures with existing ASCs, or through investment into their own facility(ies), because this growing shift is imminent in all markets for cardiology.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, CardiologistsTweet-
🚨 "A Shift in Cardiovascular Care: ASCs, PAD, and PVI" 🚨 Michael Church, Director, and Amy Newell, Senior Vice President at Corazon, Inc. Is this the next big transformation in vascular health? 🔗 Read more: https://t.co/TPXTT6syCU @InvasiveCardiol #cardiotwitter https://t.co/JVHwmXlGkK
-
-
Mashup Score: 1
Left ventricular assist devices, which are mechanical heart pumps, are an important treatment for patients with advanced heart failure.LVADs assist weakened left ventricles to enable the heart to pump blood properly, and can be used as permanent solutions to the heart failure condition or used to stabilize a patient’s heart failure condition as a bridge to transplantation. LVADs are complex
Source: www.healio.comCategories: General Medicine News, CardiologistsTweet-
Healio spoke with Francis D. Pagani, MD, PhD, why LVADs are so challenging, how the new device works and how patients with advanced HF might benefit if the trial is successful @umichCVC #cardiotwitter https://t.co/Ko9FfTrP7H
-
-
Mashup Score: 2
Danon disease is a rare, X-linked, monogenic cardiomyopathy caused by mutations in the lysosomal-associated membrane 2 gene (LAMP2), which encodes the LAMP2 protein. In male patients, the predomina…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
Update on Danon's RP-A501 gene therapy phase I Things are going well Paper is here https://t.co/0W4Qc5eKWp #CardioTwitter https://t.co/0k7lUoIbhK
-
-
Mashup Score: 0Rhode Island Hospital Cardiac Catheterization Lab - 19 day(s) ago
Rhode Island Hospital’s interventional cardiologists performed the first outpatient cardiac catheterization in New England and were among the first in the United States to perform percutaneous coronary intervention (PCI). We have a cath lab that is located just adjacent to the emergency department’s critical care unit.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, CardiologistsTweet-
Cath Lab Spotlight: Rhode Island Hospital Cardiac Cath Lab https://t.co/2cMVH93Ent @JDawnAbbott1 #cardiotwitter @invasivecardiol https://t.co/0WwaskbbO0
-
-
Mashup Score: 1Beyonttra | European Medicines Agency (EMA) - 1 month(s) ago
On 12 December 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Beyonttra 1, intended for the treatment of transthyretin amyloidosis in adult patients with cardiomyopathy. The applicant for this medicinal product is BridgeBio Europe B.V. Beyonttra will be available as 356 mg film-coated tablet. The active substance of BEYONTTRA is acoramidis hydrochloride, belonging to the pharmacothe
Source: www.ema.europa.euCategories: General Medicine News, CardiologistsTweet-
Acoramidis is Beyonttra in Europe US: Attruby #CardioTwitter https://t.co/XwsGpFb9pi. https://t.co/6bN8TkYZIm
-
Crossing Stenotic Aortic Valves During TAVR: Technical Review and Thoughts Richard Casazza, MAS, RT(R)(CI) https://t.co/IJ53x0m9Iz #cardiotwitter @InvasiveCardiol https://t.co/0vDmtg71v9